Variability in phenotype and response to treatment in chronic nonbacterial osteomyelitis; the Irish experience of a national cohort

Table 4 Treatment response among patients receiving > 1 TNF blockers

Patient	1st TNF blocker	Indication for discontinuation	2nd TNF blocker	Outcome	3rd TNF blocker	Outcome
1	Adalimumab	Worsening disease	Etanercept	Partial response	NA
9	Infliximab	Psoriasis	Adalimumab	Remission	NA
10	Adalimumab	Worsening disease	Infliximab	Anaphylactic reaction	Etanercept	No response^a
16	Adalimumab	Allergic reaction	Infliximab	Remission	NA
24	Infliximab	Worsening disease	Adalimumab	Remission	NA
30	Etanercept	Persistent symptoms	Infliximab	Remission	NA

^aPatient 10 had worsening disease on methotrexate and adalimumab, then an anaphylactic reaction to infliximab followed by a brief clinical response to etanercept and then further clinical and radiological progression of disease; this patient is now on Pamidronate and has yet to achieve remission
Clinical course and outcome

ISSN: 1546-0096